Evidence level: C
四诊六对通道里,谁冗余、谁互补的排序不是一张能贴遍所有病种的表——它随主导通道而翻,而且在协同这一侧翻得比冗余更早。
正文
前文《四诊互信息矩阵》提出过一个很干净的想法:望、闻、问、切四个通道,两两之间都有一个”冗余-互补配比”——两个通道各自携带的证候信息重合得多(冗余),还是必须联合才冒出额外信息(互补、协同)。如果这个配比结构跨病种是同一套,那四诊合参就有了张通用说明书:不管看什么病,都先抓那几对互补性最强的通道。
这一篇就干一件事:把”跨病种同构”这个假设摆到量化裁决台上,先写死判据,再报结果。判据三条,预注册式:判据一,所有病种原型之间配对排序的 Spearman 秩相关都 ≥0.7,则单张配比表全域可用;判据二,同一族内 ≥0.7 而跨族 ≤0.3,则按主导通道分族建表(三到四张);判据三,跨族全 <0.3 且置信区间跨零,则每个病种独立建表、禁止跨病种复用。
结果一:判据一死了,而且死得很难看。 以”均衡型”病种(四通道各有独立贡献、没有一个压倒性主导)为基准,五个原型里三个直接反向:问诊主导型 ρ=-0.26、脉搏主导型 0.09、闻诊(声音)主导型 -0.20。把六个原型两两配对,最低的一对是 -0.71。也就是说,某病种里”最该联合的两诊”,在另一个病种里恰好是”最不该指望的两诊”。这不是抽样噪声的问题——秩相关为负意味着排序整个颠倒过来了。
结果二:真正稳的只有一小族。 均衡型、弥漫型(四通道都很弱、信息主要来自共享成分)、舌象主导型三者之间,秩相关在 0.71 附近,勉强过线;但把舌象主导型与弥漫型直接对撞,掉到 0.14。三成员族里三角形都不闭合,说明”按主导通道分族”这条中间路线站不住——族不是想切就能切的。
结果三:冗余与协同朝相反方向动。 这是本轮最值得记的一条。同一批原型,协同占比排序的跨病种相关可以做到 0.71,而冗余占比排序的相关是 -0.89(近乎完全反向)。也就是说,两个指标不是”同一件事的两种刻度”,它们在跨病种时会互相拆台。这一点在 L1 核心里早有对应口径:冗余是”同一目标有两条通路可预测”,协同是”只有联合才有信息”,两者方向本来就可以相反。
结果四:跨病种套用一张表的代价是量得出来的。 把所有原型平均排名合成一张共识表,用它给每个病种挑”最该联合的两对通道”,再跟各病种自己算出来的最优两对对比:舌象主导型丢 36% 的可解释协同信息,闻诊主导型 27%、问诊主导型 28%,脉搏主导型只丢 10%,均衡/弥漫型 0%。最惨的单格是舌象主导型——共识表推荐的通道对,只能拿到它自己最优那一对的 22% 协同占比。16% 的加权平均代价听着不致命,但落到某个具体病种就是”跟没抓对差不多”。
为什么协同这一侧特别不稳:一条现成的文献解释。 2026 年 Panzeri 组在 Patterns 上给出的结论很直接:不管用高斯估计还是离散估计,经验部分信息分解的协同量都带显著的小样本偏差,而且这个偏差远大于冗余量的偏差,偏差差距随概率分布参数个数增加而放大(PMID 42746280)。这条正好落在本轮仿真最难看的地方——协同占比恰恰是最容易翻、最经不起跨病种比的量。换句话说,”哪张表更好看”很大程度取决于”哪张表的偏差更大”。同一时期另一条独立证据来自多模态生存预测:在 17 个 TCGA 队列、四对分子模态上,冗余与协同确实都压过模态独有信息,但偏哪边由通路结构决定——RNA-甲基化与 RNA-miRNA 偏协同,RNA-RPPA 与甲基化-RPPA 偏冗余(PMID 42546496)。同一种”多模态预测同一终点”的框架下,配比倾向就不统一,这与本轮的跨病种反转是同一个现象的两个观察面。
结果五:可信域窄得吓人。 同一病种内部做分半重跑(独立两批样本各算一遍配比表),均衡型 n=200 到 n=1000 的中位秩相关只有 0.09 到 0.26,top-1 命中率 8% 到 33%,基本到”不可重复”的程度;n=3000 中位升到 0.69、命中率 83%,才算进可信区。偏向单一通道的病种(如舌象主导型)好一些,n=500 就进 0.83。这条曲线的实践含义很硬:四诊配比表的最小样本量门槛按三千例起步,而不是几百例;低于一千例做出来的表,先当”还没测出来”处理。
可落地的折中供给。 既然单表用不了、逐病种分族又切不干净,剩下的就只有一条诚实路线:双层申报。第一层是全局共识表,只用来排”优先级提示”,不承担结论;第二层是各病种(或主导通道族)独立标定表,承担结论,且必须附样本量与分半重复性证据。工程上配一套重抽样集成式的稳定性筛选(这类做法在生物标记物场景已有成熟先例,PMID 35016102),让报表输出”排序稳定度”而非只输出”排序”。一句话总结:四诊的冗余-互补配比是有结构的,但那个结构的坐标轴是”主导通道 × 样本量”,不是”病种”。
证据与局限
已验证: 跨病种配比排序不稳定这一点在仿真里是硬的——六原型两两秩相关最低 -0.71,协同与冗余两个指标的相关方向相反(-0.89 对 0.71)。文献侧有一条独立支撑:PID 的协同估计小样本偏差显著大于冗余估计,且随参数个数放大(PMID 42746280)。另一条支撑跨模态倾向不统一:同一预测框架下四对分子模态的冗余/协同倾向由通路结构决定,16 个队列上不可统一(PMID 42546496)。
部分验证: 样本量门槛(n=3000 进可信区)来自本组仿真,不是实测;均衡型在 n=1000 仍不可重复(中位 0.26)这一档可信度较高,但是否真的要到三千例、还是换估计量(偏差校正后)能压到一千,尚无实测。集成式稳定性筛选能救排序(PMID 35016102)也只是方法学类比,没在四诊数据上做过。
待验证: 真实四诊队列的分半重复性曲线;偏差校正在真实四诊数据上能否把协同端的噪声压下来;”主导通道”这个分层变量本身该用什么指标定义(目前用仿真设定的真值负荷,实际研究里没有真值,只能靠代理);配比表与融合增益是否同源(若同源,则本表可替代消融实验的一部分)。
L1 网络状态:该主题尚未进入 L1 对应网络。最近邻为 E-061 段的「冗余度 / 协同度(PID,部分信息分解)」边,KB-509(open/中)原文:「呼吸率慢于自发呼吸频率时,冗余度在健康人与心衰两组都上升」,并附口径警告:「KB-508 测同步度、KB-509 测冗余度,两者方向可以相反(冗余 = 同一目标有两条通路可预测;协同 = 只有联合才有信息)」。该边属心肺偶联,与本篇四诊四通道配比非同一条边。
相关阅读
证据等级: C
参考文献: PMID 42746280, PMID 42546496, PMID 35016102
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Is the ranking of redundancy proportion and complementarity proportion an invariant across diseases: cross-disease stability adjudication of the four examinations and four-chann…
Evidence level: C
In the framework of the Four Examinations and Six Pairs of Channels, neither the assignment of redundancy nor that of complementarity constitutes a universal table applicable to all disease categories; rather, this ranking shifts according to the dominant channel and flips earlier on the side of synergy than on that of redundancy.
Body
The preceding Yijing Studies paper, “Four Diagnostic Mutual Information Matrix,” proposed a clean concept: the four channels—Inspection (Wang), Auscultation/Smell (Wen), Inquiry (Wen), and Palpation (Qie)—each carry diagnostic information. Between any pair of channels, there exists a “redundancy-complementarity ratio.” This ratio determines whether the overlapping information from two channels is primarily redundant (both carry similar signals) or complementary (only jointly do they reveal extra information). If this ratio structure is invariant across different disease prototypes, then the Four Diagnostics combined (Si Zhen He Can) yields a universal manual: regardless of the disease, one should first identify the pair of channels with the strongest complementarity.
This paper performs exactly that: it places the hypothesis of “cross-disease isomorphism” on a quantitative adjudication bench. First, it establishes rigid criteria; second, it reports the results. Three criteria were pre-registered:
- Criterion One: If the Spearman rank correlation between all pairwise comparisons of disease prototypes is ≥0.7, then a single ratio table applies globally.
- Criterion Two: If correlations within the same family are ≥0.7 while those across families are ≤0.3, then tables should be constructed by dominant channel (three to four tables).
- Criterion Three: If cross-family correlations are all <0.3 and confidence intervals cross zero, then each disease prototype must have its own independent table; cross-disease reuse is forbidden.
Result One: Criterion One failed, and failed badly. Using “balanced” disease prototypes (where all four channels contribute independently with no single dominant channel) as the baseline, three of the five prototypes showed direct reversal: Inquiry-dominant ρ=-0.26, Pulse-dominant 0.09, and Auscultation (sound)-dominant -0.20. Pairing all six prototypes, the lowest correlation was -0.71. This means that in one disease, the “most complementary pair” is exactly the “least expected pair” in another disease. This is not merely sampling noise; negative rank correlation implies the entire ordering is inverted.
Result Two: Only one small family is stable. Among Balanced, Diffuse (where all four channels are weak and information comes mainly from shared components), and Tongue-dominant prototypes, rank correlations hover around 0.71, barely passing the threshold. However, directly comparing Tongue-dominant with Diffuse drops to 0.14. In this three-member family, triangles do not close, indicating that “grouping by dominant channel” as an intermediate route is untenable—the families cannot be arbitrarily sliced.
Result Three: Redundancy and synergy move in opposite directions. This is the most significant finding of this round. For the same set of prototypes, the cross-disease correlation of synergy ranking reaches 0.71, while redundancy ranking correlation is -0.89 (almost completely reversed). Thus, the two metrics are not “two scales of the same thing”; they undermine each other across diseases. This corresponds precisely to the L1 core definition: redundancy means “two pathways can predict the same target,” whereas synergy means “only joint use reveals information.” Their directions can indeed be opposite.
Result Four: The cost of applying one table across diseases is quantifiable. By averaging all prototype rankings into a consensus table and using it to select the “most complementary pair” for each disease, then comparing against each disease’s own optimal pair: Tongue-dominant loses 36% of interpretable synergy, Auscultation-dominant 27%, Inquiry-dominant 28%, Pulse-dominant only 10%, and Balanced/Diffuse 0%. The worst cell is Tongue-dominant—the consensus table’s recommended pair captures only 22% of its own optimal synergy. While the weighted average cost of 16% sounds manageable, for any specific disease it amounts to “missing the mark entirely.”
Why synergy is particularly unstable: a ready literature explanation. In 2026, the Panzeri group published in Patterns a direct conclusion: regardless of whether Gaussian estimation or discrete estimation is used, the empirical partial information decomposition synergy component carries significant small-sample bias. Moreover, this bias in synergy is far larger than the redundancy bias, and the discrepancy amplifies as the number of probability distribution parameters increases (PMID 42746280). This perfectly matches the most problematic aspect of our simulation: synergy proportion is precisely the metric most prone to fluctuation and least reliable for cross-disease comparison. In other words, “which table looks better” largely depends on “which table has greater bias.”
Additionally, independent evidence from multimodal survival prediction supports this: across 17 TCGA cohorts and four pairs of molecular modalities, both redundancy and synergy exceed modality-specific information, but the direction depends on pathway structure—RNA-methylation and RNA-miRNA lean toward synergy, while RNA-RPPA and Methylation-RPPA lean toward redundancy (PMID 42546496). Under the same “multimodal prediction of one endpoint” framework, ratio tendencies are not uniform, reflecting the same phenomenon observed as cross-disease reversal in this study.
Result Five: The credible domain is shockingly narrow. Within a single disease, performing split-half re-runs (calculating ratio tables independently from two batches of samples) shows that for Balanced prototypes with n=200 to n=1000, median rank correlation ranges only from 0.09 to 0.26, top-1 hit rate from 8% to 33%, essentially “unrepeatable.” Only at n=3000 does median rise to 0.69 and hit rate to 83%, entering the credible region. Disease prototypes leaning toward a single channel (e.g., Tongue-dominant) perform better, reaching 0.83 at n=500. The practical implication is stark: the minimum sample size threshold for Four Diagnostic ratio tables starts at 3,000 cases, not hundreds; tables derived from fewer than 1,000 should be treated as “not yet measured.”
Practical compromise in data provision. Since a single table is insufficient and splitting by disease category fails to capture all nuances, the only honest approach is a two-tier reporting system. The first tier is a global consensus table used solely to generate “priority indicators,” not definitive conclusions. The second tier comprises independent standardized tables for each disease (or dominant pathway group), which bear the conclusions and must include sample size and half-split reproducibility evidence. Engineering-wise, this is paired with a resampling-based stability filter (such methods are well-established in biomarker contexts, PMID 35016102), ensuring the report outputs “ranking stability” rather than just “ranking.” In summary: the redundancy-complement ratio of the four diagnostic methods is structured, but the axes of that structure are “dominant pathway × sample size,” not “disease category.”
Evidence and Limitations
Verified: The instability of cross-disease ratio ranking in simulation is robust—the six prototypes show the lowest pairwise rank correlation at -0.71, while the directions of correlation for synergy and redundancy are opposite (-0.89 versus 0.71). Literature provides independent support: PID’s synergy estimate exhibits significant small-sample bias compared to redundancy, and this bias amplifies with the number of parameters (PMID 42746280). Another line of support concerns inconsistent cross-modal tendencies: under the same predictive framework, the redundancy/synergy tendency of four pairs of molecular modalities is determined by pathway structure and cannot be unified across 16 cohorts (PMID 42546496).
Partially Verified: The sample size threshold (n=3000 entering the credible interval) originates from our group’s simulation, not empirical measurement; the balanced type remains irreproducible at n=1000 (median 0.26), which holds higher credibility, though it remains unverified whether the threshold truly requires three thousand cases or if switching estimators (bias-corrected) could reduce it to one thousand. Ensemble stability filtering rescues ranking (PMID 35016102) serves only as a methodological analogy, without application to Four-Examination data.
Pending Verification: The split-reproducibility curve for real Four-Examination cohorts; whether bias correction suppresses noise on the synergy side using actual Four-Examination data; how to define the “dominant pathway” stratification variable (currently using true load values set in simulation, whereas real research lacks ground truth and must rely on proxies); whether the ratio table and fusion gain share the same origin (if so, this table could partially substitute for ablation experiments).
L1 Network State: This topic has not yet entered the L1-corresponding network. The nearest edge is E-061’s “Redundancy/Synergy (PID, Partial Information Decomposition)” edge. KB-509 (open/medium) states: “Redundancy increases in both healthy and heart failure groups when breathing rate lags spontaneous breathing frequency,” accompanied by a scope warning: “KB-508 measures synchrony, KB-509 measures redundancy; their directions can be opposite (redundancy = two pathways predict the same target; synergy = information exists only jointly).” This edge pertains to cardiopulmonary coupling and differs from the Four-Examination Four-Channel ratio in this paper.
Related Reading
- Four-Diagnostic Mutual Information Matrix: Isomorphism of Multi-Channel Redundancy-Complementarity in Wengwenwqie with Modern Multimodal Fusion
- What Happens When One Channel Is Missing in the Four-Diagnostic System: Degradation Curves of the Integrated Diagnostic System and Necessity of Combined Analysis
- Redundancy-Antagonism Decomposition of Sound Parameters
- Bio-Frequency Code Research Pool
Evidence Level: C
References: PMID 42746280, PMID 42546496, PMID 35016102
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply